Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

doi:10.1056/NEJM200009283431301

Volume 343:898-904		September 28, 2000		Number 13

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Lawrence D. Jacobs, M.D., Roy W. Beck, M.D., Ph.D., Jack H. Simon, M.D., Ph.D., R. Phillip Kinkel, M.D., Carol M. Brownscheidle, Ph.D., Thomas J. Murray, M.D., Nancy A. Simonian, M.D., Peter J. Slasor, Sc.D., Alfred W. Sandrock, M.D., Ph.D., for The CHAMPS Study Group

Full Text

PDF

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background Treatment with interferon beta has been shown tohelp patients with established multiple sclerosis, but it isnot known whether initiating treatment at the time of a firstclinical demyelinating event is of value.

Methods We conducted a randomized, double-blind trial of 383patients who had a first acute clinical demyelinating event(optic neuritis, incomplete transverse myelitis, or a brain-stemor cerebellar syndrome) and evidence of prior subclinical demyelinationon magnetic resonance imaging (MRI) of the brain. After initialtreatment with corticosteroids, 193 patients were randomly assignedto receive weekly intramuscular injections of 30 µg ofinterferon beta-1a and 190 were assigned to receive weekly injectionsof placebo. The study end points were the development of clinicallydefinite multiple sclerosis and changes in findings on MRI ofthe brain. The trial was stopped after a preplanned interimefficacy analysis.

Results During three years of follow-up, the cumulative probabilityof the development of clinically definite multiple sclerosiswas significantly lower in the interferon beta-1a group thanin the placebo group (rate ratio, 0.56; 95 percent confidenceinterval, 0.38 to 0.81; P=0.002). As compared with the patientsin the placebo group, patients in the interferon beta-1a grouphad a relative reduction in the volume of brain lesions (P<0.001),fewer new or enlarging lesions (P<0.001), and fewer gadolinium-enhancinglesions (P<0.001) at 18 months.

Conclusions Initiating treatment with interferon beta-1a atthe time of a first demyelinating event is beneficial for patientswith brain lesions on MRI that indicate a high risk of clinicallydefinite multiple sclerosis.

Source Information

From the Department of Neurology, State University of New York School of Medicine at Buffalo and Buffalo General Hospital, Buffalo (L.D.J., C.M.B.); the Jaeb Center for Health Research, Tampa, Fla. (R.W.B.); the Department of Radiology–MRI, University of Colorado Health Sciences Center, Denver (J.H.S.); the Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland (R.P.K.); the Multiple Sclerosis Research Unit, Centre for Clinical Research, Victoria General Hospital, Queen Elizabeth II Health Sciences Centre, Halifax, N.S., Canada (T.J.M.); and Biogen, Cambridge, Mass. (N.A.S., P.J.S., A.W.S.).

Address reprint requests to Dr. Jacobs at the Department of Neurology, Buffalo General Hospital, 100 High St., Buffalo, NY 14203, or at ljacobs{at}kaleidahealth.org.

Full Text of this Article

Related Letters:

Interferon Beta-1a during a First Demyelinating Event
Poser C. M., Esmonde T. F.G., Jacobs L. D., Beck R. W., Kinkel R. P.
Extract | Full Text | PDF
N Engl J Med 2001; 344:229-230, Jan 18, 2001. Correspondence

This article has been cited by other articles:

Volpe, N. J. (2008). The Optic Neuritis Treatment Trial: A Definitive Answer and Profound Impact With Unexpected Results. Arch Ophthalmol 126: 996-999 [Full Text]
Patten, S., Williams, J., Metz, L. (2008). Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler 14: 406-411 [Abstract]
Chen, J. W., Breckwoldt, M. O., Aikawa, E., Chiang, G., Weissleder, R. (2008). Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 131: 1123-1133 [Abstract] [Full Text]
Polman, C. H., Reingold, S. C., Barkhof, F., Calabresi, P. A., Clanet, M., Cohen, J. A., Cutter, G. R., Freedman, M. S., Kappos, L., Lublin, F. D., McFarland, H. F., Metz, L. M., Miller, A. E., Montalban, X., O'Connor, P. W., Panitch, H., Richert, J. R., Petkau, J., Schwid, S. R., Sormani, M. P., Thompson, A. J., Weinshenker, B. G., Wolinsky, J. S. (2008). Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology 70: 1134-1140 [Abstract] [Full Text]
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., Miller, D. H. (2008). Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131: 808-817 [Abstract] [Full Text]
Lebrun, C, Bensa, C, Debouverie, M, De Seze, J, Wiertlievski, S, Brochet, B, Clavelou, P, Brassat, D, Labauge, P, Roullet, E, on behalf of CFSEP, (2008). Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J. Neurol. Neurosurg. Psychiatry 79: 195-198 [Abstract] [Full Text]
Tomassini, V., De Giglio, L., Reindl, M., Russo, P., Pestalozza, I., Pantano, P., Berger, T., Pozzilli, C. (2007). Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 13: 1086-1094 [Abstract]
Pohlau, D., Przuntek, H., Sailer, M., Bethke, F., Koehler, J., Konig, N., Heesen, C., Spath, P., Andresen, I. (2007). Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 13: 1107-1117 [Abstract]
Barkhof, F., Polman, C. H., Radue, E.-W., Kappos, L., Freedman, M. S., Edan, G., Hartung, H.-P., Miller, D. H., Montalban, X., Poppe, P., de Vos, M., Lasri, F., Bauer, L., Dahms, S., Wagner, K., Pohl, C., Sandbrink, R. (2007). Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results. Arch Neurol 64: 1292-1298 [Abstract] [Full Text]
Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., Rostami, A. (2007). SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis. IOVS 48: 3602-3609 [Abstract] [Full Text]
Pelayo, R., Tintore, M., Rovira, A., Rio, J., Nos, C., Grive, E., Tellez, N., Comabella, M., Montalban, X. (2007). Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. Mult Scler 13: 731-736 [Abstract]
Ross, A. P. (2007). Treatment strategies across the multiple sclerosis lifespan. Neurology 68: S1-S2 [Full Text]
Coyle, P. K. (2007). Evidence-based medicine and clinical trials. Neurology 68: S3-S7 [Abstract] [Full Text]
Thrower, B. W. (2007). Clinically isolated syndromes: Predicting and delaying multiple sclerosis. Neurology 68: S12-S15 [Abstract] [Full Text]
Noronha, A. (2007). Neutralizing antibodies to interferon. Neurology 68: S16-S22 [Abstract] [Full Text]
Frohman, E. M., Kerr, D. (2007). Is Neuromyelitis Optica Distinct From Multiple Sclerosis?: Something for "Lumpers" and "Splitters". Arch Neurol 64: 903-905 [Full Text]
Farrell, R. A, Giovannoni, G. (2007). Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis. Mult Scler 13: 567-577 [Abstract]
Zivadinov, R., Locatelli, L., Cookfair, D., Srinivasaraghavan, B., Bertolotto, A., Ukmar, M., Bratina, A., Maggiore, C., Bosco, A., Grop, A., Catalan, M., Zorzon, M. (2007). I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 13: 490-501 [Abstract]
Goelz, S. E., Walt, L. (2007). Development of neutralizing antibodies to intramuscular interferon beta-1a (Avonex (R)). Mult Scler 13: 14-20 [Abstract]
Pohl, D., Waubant, E., Banwell, B., Chabas, D., Chitnis, T., Weinstock-Guttman, B., Tenembaum, S., for the International Pediatric MS Study Group, (2007). Treatment of pediatric multiple sclerosis and variants. Neurology 68: S54-S65 [Abstract] [Full Text]
Koch, M. W., Mostert, J. P., de Vries, J. J., De Keyser, J., Kappos, L ., Polman, C .H., Freedman, M .S., Edan, G ., Hartung, H .-P., Miller, D .H., Montalban, X ., Barkhof, F ., Bauer, L ., Pohl, C ., Sandbrink, R . (2007). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 68: 1163-1164 [Full Text]
Goodin, D. S., Frohman, E. M., Hurwitz, B., O'Connor, P. W., Oger, J. J., Reder, A. T., Stevens, J. C. (2007). Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68: 977-984 [Abstract] [Full Text]
Sominanda, A, Rot, U, Suoniemi, M, Deisenhammer, F, Hillert, J, Fogdell-Hahn, A (2007). Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13: 208-214 [Abstract]
Lynch, R. A., Etchin, J., Battle, T. E., Frank, D. A. (2007). A Small-Molecule Enhancer of Signal Transducer and Activator of Transcription 1 Transcriptional Activity Accentuates the Antiproliferative Effects of IFN-{gamma} in Human Cancer Cells. Cancer Res. 67: 1254-1261 [Abstract] [Full Text]
Jenkins, P. F. (2007). The Multiple Facets of Multiple Sclerosis. Amer. Orthoptic Jrnl. 57: 69-78 [Abstract]
Gneiss, C, Tripp, P, Reichartseder, F, Egg, R, Ehling, R, Lutterotti, A, Khalil, M, Kuenz, B, Mayringer, I, Reindl, M, Berger, T, Deisenhammer, F (2006). Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 12: 731-737 [Abstract]
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., Pohl, C., Sandbrink, R., for the BENEFIT Study Group, (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249 [Abstract] [Full Text]
Noseworthy, J. H. (2006). How much can we learn from long-term extension trials in multiple sclerosis?. Neurology 67: 930-931 [Full Text]
Kappos, L., Traboulsee, A., Constantinescu, C., Eralinna, J. -P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., Uitdehaag, B., Li, D. (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.. Neurology 67: 944-953 [Abstract] [Full Text]
Goodin, D. S., Kinkel, R. P., Kollman, C. (2006). IM interferon {beta}-1a delays definite multiple sclerosis 5 years after a first demyelinating event.. Neurology 67: 1104-1105 [Full Text]
Wattjes, M.P., Harzheim, M., Kuhl, C.K., Gieseke, J., Schmidt, S., Klotz, L., Klockgether, T., Schild, H.H., Lutterbey, G.G. (2006). Does High-field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis?. Am. J. Neuroradiol. 27: 1794-1798 [Abstract] [Full Text]
Chang, K H, Lyu, R K, Chen, C M, Hsu, W C, Wu, Y R, Chen, S T, Ro, L S (2006). Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study. Mult Scler 12: 501-506 [Abstract]
Dorfman, L., Balcer, L. J. (2006). Optic neuritis.. NEJM 355: 212-212 [Full Text]
Sorensen, P. S., Koch-Henriksen, N., Ravnborg, M., Frederiksen, J. L., Jensen, K a., Heltberg, A., Schaldemose, H., Deth, S., Kristensen, O l., Worm, M., Stenager, E., Hansen, H. J., Sivertsen, B., Torring, J., Danish Multiple Sclerosis Study Group, (2006). Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 12: 253-264 [Abstract]
Fraser, C., Klistorner, A., Graham, S., Garrick, R., Billson, F., Grigg, J. (2006). Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis.. Arch Neurol 63: 847-850 [Abstract] [Full Text]
Pittock, S. J., Weinshenker, B. G., Noseworthy, J. H., Lucchinetti, C. F., Keegan, M., Wingerchuk, D. M., Carter, J., Shuster, E., Rodriguez, M. (2006). Not every patient with multiple sclerosis should be treated at time of diagnosis.. Arch Neurol 63: 611-614 [Full Text]
Frohman, E. M., Havrdova, E., Lublin, F., Barkhof, F., Achiron, A., Sharief, M. K., Stuve, O., Racke, M. K., Steinman, L., Weiner, H., Olek, M., Zivadinov, R., Corboy, J., Raine, C., Cutter, G., Richert, J., Filippi, M. (2006). Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.. Arch Neurol 63: 614-619 [Full Text]
Balcer, L. J. (2006). Clinical practice. Optic neuritis.. NEJM 354: 1273-1280 [Full Text]
CHAMPIONS Study Group, (2006). IM interferon {beta}-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678-684 [Abstract] [Full Text]
Murray, T J (2006). Diagnosis and treatment of multiple sclerosis.. BMJ 332: 525-527 [Full Text]
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., Sandrock, A. W., the AFFIRM Investigators, (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.. NEJM 354: 899-910 [Abstract] [Full Text]
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., the SENTINEL Investigators, (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.. NEJM 354: 911-923 [Abstract] [Full Text]
Masjuan, J., Alvarez-Cermeno, J. C., Garcia-Barragan, N., Diaz-Sanchez, M., Espino, M., Sadaba, M. C., Gonzalez-Porque, P., San Millan, J. M., Villar, L. M. (2006). Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS. Neurology 66: 576-578 [Abstract] [Full Text]
Rovaris, M., Gambini, A., Gallo, A., Falini, A., Ghezzi, A., Benedetti, B., Sormani, M. P., Martinelli, V., Comi, G., Filippi, M. (2005). Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 65: 1626-1630 [Abstract] [Full Text]
(2005). Additional Information. JAMA 294: E1-E3 [Full Text]
Iskedjian, M., Walker, J. H, Gray, T., Vicente, C., Einarson, T. R, Gehshan, A. (2005). Economic evaluation of Avonex(R) (interferon beta-1a) in patients following a single demyelinating event. Mult Scler 11: 542-551 [Abstract]
Mikol, D, Lopez-Bresnahan, M, Taraskiewicz, S, Chang, P, Rangnow, J, RebijectTM Study Group, (2005). A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif(R)) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 11: 585-591 [Abstract]
Frohman, E. M., Stuve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R., Sorensen, P. S., Phillips, J. T., Weinshenker, B., Hawker, K., Hartung, H.-P., Steinman, L., Zamvil, S., Cree, B. A. C., Hauser, S., Weiner, H., Racke, M. K., Filippi, M. (2005). Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations. Arch Neurol 62: 1519-1530 [Abstract] [Full Text]
Becker, M D, Heiligenhaus, A, Hudde, T, Storch-Hagenlocher, B, Wildemann, B, Barisani-Asenbauer, T, Thimm, C, Stubiger, N, Trieschmann, M, Fiehn, C (2005). Interferon as a treatment for uveitis associated with multiple sclerosis. Br. J. Ophthalmol. 89: 1254-1257 [Abstract] [Full Text]
Scott, T. F, Kassab, S. L, Singh, S. (2005). Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler 11: 373-377 [Abstract]
de Seze, J, Vermersch, P (2005). Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. Mult Scler 11: 395-397 [Abstract]
Herndon, R. M, Rudick, R. A, Munschauer, F. E III, Mass, M. K, Salazar, A. M, Coats, M. E, Labutta, R., Richert, J. R, Cohan, S. L, Genain, C., Goodkin, D., Toal, M., Riester, K. (2005). Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis. Mult Scler 11: 409-419 [Abstract]
Kappos, L., Clanet, M., Sandberg-Wollheim, M., Radue, E. W., Hartung, H. P., Hohlfeld, R., Xu, J., Bennett, D., Sandrock, A., Goelz, S., the European Interferon Beta-1a IM Dose-Comparison, (2005). Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study. Neurology 65: 40-47 [Abstract] [Full Text]
Wessely, R. (2005). Interference by interferons: Janus faces in vascular proliferative diseases. Cardiovasc Res 66: 433-443 [Abstract] [Full Text]
Chaudhuri, A., Behan, P.O. (2005). Treatment of multiple sclerosis: beyond the NICE guidelines. QJM 98: 373-378 [Abstract] [Full Text]
Pandya, R., Metz, L., Patten, S. B. (2005). Predictive Value of the CES-D in Detecting Depression Among Candidates for Disease-Modifying Multiple Sclerosis Treatment. Psychosomatics 46: 131-134 [Abstract] [Full Text]
Siegert, R J, Abernethy, D A (2005). Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 76: 469-475 [Abstract] [Full Text]
Uitdehaag, B. M., Kappos, L., Bauer, L., Freedman, M. S, Miller, D., Sandbrink, R., Polman, C. H (2005). Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler 11: 227-231 [Abstract]
Villar, L. M., Masjuan, J., Sadaba, M. C., Gonzalez-Porque, P., Plaza, J., Bootello, A., Alvarez-Cermeno, J. C. (2005). Early Differential Diagnosis of Multiple Sclerosis Using a New Oligoclonal Band Test. Arch Neurol 62: 574-577 [Abstract] [Full Text]
Freedman, M S, Francis, G S, Sanders, E A., Rice, G P., O'Connor, P, Comi, G, Duquette, P, Metz, L, Murray, T J, Bouchard, J-P, Abramsky, O, Pelletier, J, O'Brien, F, OWIMS Study Group, , University of British Columbia MS/MRI Research Gro, (2005). Randomized study of once-weekly interferon {beta}-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11: 41-45 [Abstract]
O'Rourke, K E., Hutchinson, M (2005). Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11: 46-50 [Abstract]
Bakshi, R., Hutton, G. J., Miller, J. R., Radue, E.-W. (2004). The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology 63: S3-S11 [Abstract] [Full Text]
Stuart, W. H., Cohan, S., Richert, J. R., Achiron, A. (2004). Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology 63: S19-S27 [Abstract] [Full Text]
Vartanian, T. K., Zamvil, S. S., Fox, E., Sorensen, P. S. (2004). Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63: S42-S49 [Abstract] [Full Text]
Espejo, C, Brieva, L, Ruggiero, G, Rio, J, Montalban, X, Martinez-Caceres, E M (2004). IFN-{beta} treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis. Mult Scler 10: 630-635 [Abstract]
The North American Study Group on Interferon beta-, (2004). Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63: 1788-1795 [Abstract] [Full Text]
Gneiss, C, Reindl, M, Lutterotti, A, Ehling, R, Egg, R, Khalil, M, Berger, T, Deisenhammer, F (2004). Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10: 507-510 [Abstract]
Vollmer, T L, Phillips, J T, Goodman, A D, Agius, M A, Libonati, M A, Giacchino, J L, Grundy, J S (2004). An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis. Mult Scler 10: 511-520 [Abstract]
Achiron, A., Kishner, I., Sarova-Pinhas, I., Raz, H., Faibel, M., Stern, Y., Lavie, M., Gurevich, M., Dolev, M., Magalashvili, D., Barak, Y. (2004). Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Arch Neurol 61: 1515-1520 [Abstract] [Full Text]
Uitdehaag, B. M. J., Geurts, J. J. G., Barkhof, F., Polman, C. H., Goodin, D. S., Frohman, E. M. (2004). The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee. Neurology 63: 1140-1140 [Full Text]
Bertolotto, A, Sala, A, Malucchi, S, Marnetto, F, Caldano, M, Di Sapio, A, Capobianco, M, Gilli, F (2004). Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 75: 1294-1299 [Abstract] [Full Text]
Coombs, B. D, Best, A., Brown, M. S, Miller, D. E, Corboy, J., Baier, M., Simon, J. H (2004). Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler 10: 392-397 [Abstract]
Nos, C., Sastre-Garriga, J., Borrlas, C., Rio, J., Tintore, M., Montalban, X. (2004). Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult Scler 10: 413-416 [Abstract]
Andersen, O, Elovaara, I, Farkkila, M, Hansen, H J, Mellgren, S I, Myhr, K-M, Sandberg-Wollheim, M, Soelberg Sorensen, P (2004). Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 75: 706-710 [Abstract] [Full Text]
Gordon, J. M., Frohman, E. M. (2004). The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee. Neurology 62: 838-838 [Full Text]
Pittock, S. J., Mayr, W. T., McClelland, R. L., Jorgensen, N. W., Weigand, S. D., Noseworthy, J. H., Rodriguez, M. (2004). Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62: 601-606 [Abstract] [Full Text]
Minneboo, A., Barkhof, F., Polman, C. H., Uitdehaag, B. M. J., Knol, D. L., Castelijns, J. A. (2004). Infratentorial Lesions Predict Long-term Disability in Patients With Initial Findings Suggestive of Multiple Sclerosis. Arch Neurol 61: 217-221 [Abstract] [Full Text]
Pittock, S. J., Mayr, W. T., McClelland, R. L., Jorgensen, N. W., Weigand, S. D., Noseworthy, J. H., Weinshenker, B. G., Rodriguez, M. (2004). Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 62: 51-59 [Abstract] [Full Text]
Maguire, G. A., Mantegazza, R., Chaudhuri, A., Behan, P. O., Berger, T., Reindl, M. (2003). Antimyelin Antibodies in Multiple Sclerosis. NEJM 349: 2269-2271 [Full Text]
Salama, H. H., Hong, J., Zang, Y. C. Q., El-Mongui, A., Zhang, J. (2003). Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 126: 2638-2647 [Abstract] [Full Text]
Giovannoni, G. (2003). Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies. Neurology 61: S13-17 [Abstract] [Full Text]
Zipoli, V, Portaccio, E, Siracusa, G, Pracucci, G, Sorbi, S, Amato, M P (2003). Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. Mult Scler 9: 481-485 [Abstract]
Frohman, E. M., Goodin, D. S., Calabresi, P. A., Corboy, J. R., Coyle, P. K., Filippi, M., Frank, J. A., Galetta, S. L., Grossman, R. I., Hawker, K., Kachuck, N. J., Levin, M. C., Phillips, J. T., Racke, M. K., Rivera, V. M., Stuart, W. H. (2003). The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 602-611 [Abstract] [Full Text]
Weinstock-Guttman, B., Badgett, D., Patrick, K., Hartrich, L., Santos, R., Hall, D., Baier, M., Feichter, J., Ramanathan, M. (2003). Genomic Effects of IFN-{beta} in Multiple Sclerosis Patients. J. Immunol. 171: 2694-2702 [Abstract] [Full Text]
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., Reindl, M. (2003). Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event. NEJM 349: 139-145 [Abstract] [Full Text]
Di Legge, S, Piattella, M C, Pozzilli, C, Pantano, P, Caramia, F, Pestalozza, I F, Paolillo, A, Lenzi, G L (2003). Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Mult Scler 9: 302-306 [Abstract]
Prosser, L. A, Kuntz, K. M, Bar-Or, A., Weinstein, M. C (2003). Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 9: 311-319 [Abstract]
Jin, Y P, de Pedro-Cuesta, J, Huang, Y H, Soderstrom, M (2003). Predicting multiple sclerosis at optic neuritis onset. Mult Scler 9: 135-141 [Abstract]
Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E., Melis, F., Marnetto, F., Lindberg, R. L.P., Bottero, R., Di Sapio, A., Giordana, M. T. (2003). Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients. Neurology 60: 634-639 [Abstract] [Full Text]
Sudlow, C. L M, Counsell, C. E (2003). Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 326: 388-392 [Full Text]
Frohman, E. M, Frohman, T. C (2003). Horizontal monocular saccadic failure: an unusual clinically isolated syndrome progressing to multiple sclerosis. Mult Scler 9: 55-58 [Abstract]
Giovannoni, G., Bever, C. T. Jr. (2003). Patients with clinically isolated syndromes suggestive of MS: Does MRI allow earlier diagnosis?. Neurology 60: 6-7 [Full Text]

Comments and questions? Please contact us.